# Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

> **NCT04725448** · PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 27 (estimated)

## Conditions studied

- Pulmonary Sarcomatoid Carcinoma
- Non-small Cell Lung Cancer
- Lung Diseases
- Thoracic Neoplasms

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Bevacizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04725448
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-06
- **Primary completion:** 2022-03-01
- **Final completion:** 2023-11-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725448, "Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04725448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*